CHMP5 and COVID-19: For example, the TMPRSS2 inhibitors camostat and nafamostat had been approved for the treatment of pancreatitis in Japan and were repurposed for a potential treatment of COVID-19 since they efficiently block SARS-CoV-2 Spike cleavage in vitro [130].